PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
-16.18%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
7.12%
Other expenses change of 7.12% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
-22.68%
Operating expenses reduction while Biotechnology median is 1.07%. Seth Klarman would investigate advantages.
-22.68%
Total costs reduction while Biotechnology median is 1.62%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
7.12%
D&A change of 7.12% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
22.73%
EBITDA change of 22.73% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
22.68%
Income change of 22.68% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
26.92%
Other expenses change of 26.92% versus flat Biotechnology. Walter Schloss would verify control.
22.99%
Income change of 22.99% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense change of 100.00% versus flat Biotechnology. Walter Schloss would verify strategy.
22.99%
Income change of 22.99% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
38.32%
EPS change of 38.32% versus flat Biotechnology. Walter Schloss would verify quality.
38.32%
Diluted EPS change of 38.32% versus flat Biotechnology. Walter Schloss would verify quality.
24.80%
Share count reduction below 50% of Biotechnology median of 0.17%. Jim Chanos would check for issues.
24.80%
Diluted share reduction below 50% of Biotechnology median of 0.12%. Jim Chanos would check for issues.